Clinical Trial Update: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) [Phase 2]

View source ↗

Summary

Clinical trial update for the DESTINY-Gastric03 study, a Phase 1b/2 investigation of trastuzumab deruxtecan (T-DXd) combinations in advanced HER2-expressing gas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING